CAR T therapy shows promise for severe autoimmune diseases

A blood-cancer tool moved into autoimmunity

CAR T therapy is being recast as a possible reset button for the immune system, not just a weapon against blood cancers. In severe autoimmune disease, the idea is straightforward but ambitious: engineer a patient’s T cells to remove the B cells that are driving runaway inflammation, then see whether the immune system can settle into a lasting remission without the usual cycle of chronic immunosuppression.

That shift has been most visible in B-cell-driven diseases such as systemic lupus erythematosus, idiopathic inflammatory myositis and systemic sclerosis. The rationale is that if the abnormal immune memory can be deeply depleted, the immune system may rebuild in a less destructive state. The American Society for Transplantation and Cellular Therapy has described this as a possible way to “reset” rogue autoimmunity, while stressing that the real test will be whether the response lasts beyond the first wave of early results.

What the first major study found

The strongest early clinical signal came from a New England Journal of Medicine case series from the Erlangen group, led by Georg Schett, Fabian Müller, Jule Taubmann, Andreas Mackensen and Laura Bucci at Friedrich-Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen in Germany. The study treated 15 patients in all: 8 with severe systemic lupus erythematosus, 3 with idiopathic inflammatory myositis, and 4 with systemic sclerosis.

Every patient received a single infusion of CD19 CAR T cells after preconditioning chemotherapy with fludarabine and cyclophosphamide. At a median follow-up of 15 months, all eight lupus patients had achieved DORIS remission. All three patients with idiopathic inflammatory myositis met an ACR-EULAR major clinical response, and all four patients with systemic sclerosis improved on the EUSTAR activity index. Just as striking, immunosuppressive therapy was stopped in every patient in the series.

The biologic effect was also clear. Mean B-cell aplasia lasted 112 plus or minus 47 days, showing that the therapy produced a substantial, but not necessarily permanent, wipeout of the targeted B-cell population. Grade 1 cytokine release syndrome occurred in 10 patients, a reminder that even in this small autoimmune cohort, CAR T therapy still carried the familiar immune-activation risks seen in oncology.

Why the results matter

For patients who have exhausted standard options, the appeal of CAR T is not merely that it can reduce symptoms. The hope is that it can produce durable, drug-free remission after years of escalating treatment. That is why these early data have drawn so much attention from specialty groups and patient advocates: the prospect is not just control of disease, but a possible recalibration of immune function itself.

The Lupus Foundation of America said the early findings were potentially safe and effective, while also emphasizing that future clinical studies are needed to confirm sustained, drug-free remission. That caution matters. A case series, even an unusually strong one, is not yet a standard of care. It is a signal that the strategy is biologically plausible and clinically intriguing, but still unproven at the scale needed for routine practice.

The major hurdles ahead

The biggest unanswered question is durability. A median follow-up of 15 months is encouraging, especially alongside remission in every lupus patient and major response across the myositis and systemic sclerosis groups, but autoimmune disease often unfolds over years. The field still needs controlled trials that can show whether these benefits persist, whether relapse returns once B cells recover, and whether some patients will need retreatment.

Safety is another barrier. Grade 1 cytokine release syndrome was reported in 10 of the 15 patients, which suggests the treatment was manageable in this group, but CAR T remains a high-intensity cellular therapy. The requirement for preconditioning chemotherapy with fludarabine and cyclophosphamide also means the therapy is not simple to deliver, especially in patients who are already medically fragile from long-standing autoimmune disease.

Access is likely to be the steepest challenge of all. CAR T treatments are expensive, logistically complex and concentrated in highly specialized centers. That makes the current model a high-touch intervention for a relatively small number of patients, not an easily distributed therapy. If CAR T is to move from landmark case series to broader clinical use, the field will need simpler manufacturing, clearer eligibility rules and evidence that the benefit justifies the cost and risk.

The next wave of trials is already underway

The momentum did not stop with the Erlangen report. By 2025, clinical trial registries and company announcements showed multiple Phase 1 studies advancing in severe refractory autoimmune disease. Among the most important is Bristol Myers Squibb’s CD19-directed CC-97540, also known as BMS-986353, a multicenter open-label trial for severe refractory autoimmune diseases.

That study is designed to enroll an estimated 270 participants and includes systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis and rheumatoid arthritis. It began on September 13, 2023, and has an estimated primary completion date of August 29, 2028. The scale alone signals how seriously the field is treating the question of whether this platform can move beyond a handful of dramatic individual responses.

Researchers are also testing alternative designs, including switchable CAR-T products and allogeneic or co-infused approaches. Those versions are aimed at the same basic goal, durable immune control, but with different strategies for making treatment safer, more flexible and easier to deliver. That diversification reflects both the optimism generated by the first results and the reality that the original model still faces major manufacturing and safety constraints.

What to watch next

The current evidence supports a measured conclusion: CAR T therapy may open a new path for patients with the most severe, treatment-refractory autoimmune disease, especially where B cells are central to the disease process. The early remissions are hard to ignore, and the ability to stop immunosuppressive therapy in all 15 patients is especially notable.

Even so, this is still an experimental frontier. The next chapter will be written by larger trials, longer follow-up and a much harder question than whether CAR T can work in isolated cases: whether it can become a durable, scalable option for patients who have run out of conventional choices.